Changeflow GovPing Pharma & Drug Safety CD8-specific capture agents, compositions, and ...
Routine Notice Added Final

CD8-specific capture agents, compositions, and methods of using and making

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted Regeneron Pharmaceuticals patent US12594350B2 covering stable peptide-based CD8 capture agents for use as detection agents. The patent was issued April 7, 2026, naming Regeneron Pharmaceuticals, Inc. as assignee and Heather Dawn Agnew and Bert Tsunyin Lai as inventors. The application, filed April 4, 2017 (Application No. 15478596), contains 13 claims.

What changed

The USPTO issued patent US12594350B2 to Regeneron Pharmaceuticals on April 7, 2026, covering CD8-specific peptide capture agents, compositions, and methods of using and making them for detection applications. The patent contains 13 claims and was filed under Application No. 15478596. The invention relates to stable peptide-based CD8 capture agents and methods of manufacturing for use as detection agents.

Pharmaceutical and biotechnology companies developing CD8 detection assays, related diagnostic products, or therapeutic applications involving CD8 proteins should evaluate potential freedom-to-operate implications. This patent grant does not impose compliance deadlines or reporting requirements but establishes enforceable intellectual property rights that may affect R&D activities in this space.

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

CD8-specific capture agents, compositions, and methods of using and making

Grant US12594350B2 Kind: B2 Apr 07, 2026

Assignee

Regeneron Pharmaceuticals, Inc.

Inventors

Heather Dawn Agnew, Bert Tsunyin Lai

Abstract

The present application provides stable peptide-based CD8 capture agents and methods of use as detection agents. The application further provides methods of manufacturing CD8 capture agents.

CPC Classifications

A61K 51/08 C07K 7/06 C07K 14/001 C07K 14/70517 G01N 33/534 G01N 33/56792 G01N 33/68 G01N 2333/70517 G01N 33/56972

Filing Date

2017-04-04

Application No.

15478596

Claims

13

View original document →

Named provisions

CD8-specific capture agents, compositions, and methods of using and making

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594350B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Intellectual Property
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!